Company Overview - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation products for inflammatory bowel disease (IBD) and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [3]. Upcoming Events - The company will report interim results from the Phase 1 SPY002 healthy volunteer trials on June 17, 2025, and will host a conference call and webcast at 8:00 am ET to discuss these results [1]. Product Pipeline - Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, which are aimed at treating IBD and other immune-mediated diseases [3].

Group 1 - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [1][2] - The company will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 4, 2025, and Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 [1] - Live audio webcasts and replays of the investor events will be accessible on Spyre's investor events website [1] Group 2 - Spyre's product pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, indicating a strong focus on next-generation therapies for IBD and immune-mediated diseases [2] - The company emphasizes a combination of best-in-class antibody engineering and dose optimization in its research and development efforts [2]